newsfilter
← Latest News
GlobeNewswire·

Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF), announced today that patient recruitment and dosing has begun in Turkey for the Phase II trial for